Inhibition of SLC1A5 sensitizes colorectal cancer to cetuximab

Recent developments in the treatment of metastatic colorectal cancer

(2017) Jonathan M. Loree et al.   Therapeutic Advances in Medical Oncology

FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer

(2016) L Marzi et al.   BRITISH JOURNAL OF CANCER

ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis

(2016) Haiquan Lu et al.   CANCER LETTERS

HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models

(2016) Dongsheng Wang et al.   CLINICAL CANCER RESEARCH

Rapid Diminution in the Level and Activity of DNA-Dependent Protein Kinase in Cancer Cells by a Reactive Nitro-Benzoxadiazole Compound

(2016) Viviane Silva et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Theranostic, pH-Responsive, Doxorubicin-Loaded Nanoparticles Inducing Active Targeting and Apoptosis for Advanced Gastric Cancer

(2015) Huanrong Ma et al.   BIOMACROMOLECULES

Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development

(2015) Qian Wang et al.   JOURNAL OF PATHOLOGY

Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer

(2015) YUQI SU et al.   Molecular Medicine Reports

Exploiting replicative stress to treat cancer

(2015) Matthias Dobbelstein et al.   NATURE REVIEWS DRUG DISCOVERY

ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer

(2015) M van Geldermalsen et al.   ONCOGENE

New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?

(2015) Giuseppe Bronte et al.   Oncotarget

Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer

(2014) T. M. Brand et al.   MOLECULAR CANCER THERAPEUTICS

Metformin Sensitizes Prostate Cancer Cells to Radiation Through EGFR/p-DNA-PKCSIn VitroandIn Vivo

(2014) Tingting Zhang et al.   RADIATION RESEARCH

Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution

(2014) S. Misale et al.   Cancer Discovery

Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia

(2013) L. Willems et al.   BLOOD

Stalling the Engine of Resistance: Targeting Cancer Metabolism to Overcome Therapeutic Resistance

(2013) E. B. Butler et al.   CANCER RESEARCH

Glutamine and cancer: cell biology, physiology, and clinical opportunities

(2013) Christopher T. Hensley et al.   JOURNAL OF CLINICAL INVESTIGATION

The SLC1 high-affinity glutamate and neutral amino acid transporter family

(2013) Yoshikatsu Kanai et al.   MOLECULAR ASPECTS OF MEDICINE

SLC1A5 Mediates Glutamine Transport Required for Lung Cancer Cell Growth and Survival

(2012) M. Hassanein et al.   CLINICAL CANCER RESEARCH

Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions

(2012) Isabelle Soerjomataram et al.   LANCET

The role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agents

(2012) M Z Lin et al.   ONCOGENE

Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor

(2012) M Iida et al.   ONCOGENE

Targeting C4-Demethylating Genes in the Cholesterol Pathway Sensitizes Cancer Cells to EGF Receptor Inhibitors via Increased EGF Receptor Degradation

(2012) Anna Sukhanova et al.   Cancer Discovery

Resistance to EGFR-Targeted Therapy: A Family Affair

(2011) Gregory Vlacich et al.   CANCER CELL

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Mutant onco-proteins as drug targets: successes, failures, and future prospects

(2011) Frank McCormick   CURRENT OPINION IN GENETICS & DEVELOPMENT

γH2AX: a sensitive molecular marker of DNA damage and repair

(2010) L-J Mah et al.   LEUKEMIA

Nuclear trafficking of the epidermal growth factor receptor family membrane proteins

(2010) Y-N Wang et al.   ONCOGENE

The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation

(2010) I. Vivanco et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bidirectional Transport of Amino Acids Regulates mTOR and Autophagy

(2009) Paul Nicklin et al.   CELL

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nuclear EGFR contributes to acquired resistance to cetuximab

(2009) C Li et al.   ONCOGENE

Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells

(2009) J. Yun et al.   SCIENCE

EGFR Antagonists in Cancer Treatment

(2008) Fortunato Ciardiello et al.   NEW ENGLAND JOURNAL OF MEDICINE